Section Arrow
ADAG.NASDAQ
- Adagene
Quotes are at least 15-min delayed:2024/04/29 15:43 EDT
Last
 2.23
-0.16 (-6.69%)
Day High 
2.47 
Prev. Close
2.39 
1-M High
3.45 
Volume 
48.38K 
Bid
2.23
Ask
2.45
Day Low
2.2 
Open
2.44 
1-M Low
2.32 
Market Cap 
105.54M 
Currency USD 
P/E -- 
%Yield
10-SMA 2.6 
20-SMA 2.76 
50-SMA 2.89 
52-W High 4.38 
52-W Low 1.1001 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.44/-1.63
Enterprise Value
119.25M
Balance Sheet
Book Value Per Share
1.60
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
18.11M
Operating Revenue Per Share
0.51
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.9995+0.1394+16.21%-- 
JAGXJaguar Health0.2014+0.0214+11.89%-- 
IBRXImmunityBio8.785+1.435+19.52%-- 
GERNGeron Corp4.175+0.385+10.16%-- 
XFORX4 Pharmaceuticals1.14-0.025-2.15%-- 
Quotes are at least 15-min delayed:2024/04/29 15:43 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.